Skip to main content
Premium Trial:

Request an Annual Quote

NeoProteomics Licenses Technology from Case Western Reserve University

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Biomarker development and software firm NeoProteomics announced late on Friday that it has reached an exclusive option agreement to license technologies from Case Western Reserve University.

Under the agreement, NeoProteomics will have access to tools and biomarkers that will expand its portfolio in personalized medicine, according to a statement from the university. "The deal has potential to enhance various forms of treatment of cancer, diabetes, and inflammatory diseases," it added.

Founded in 2006 and based in Cleveland, NeoProteomics identifies and validates protein biomarkers "and seeks to spearhead the development of unique and improved analysis tools," Case Western Reserve said.

Financial and other terms of the deal were not disclosed.

NeoProteomics was co-founded by John Schenkel and Mark Chance. Schenkel is currently president and CEO of NeoProteomics.

Chance, who now serves as the company's chief scientific officer, is also director of the Case Center for Proteomics and Bioinformatics and is a professor and interim chair in the department of genetics at the university's School of Medicine.

NeoProteomics is distributing software licensed from Case Western Reserve called ProtMapMS, which automates mass spectrometry workflows. The university said the software has been licensed to major drug manufacturers and a number of prestigious research universities.

The company will offer other bioinformatics software, currently under development, from the Case Western Reserve for the integration of high-throughput genomics and proteomics data in clinical research.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.